Translational Autoimmunity, Volume 2

Treatment of Autoimmune Diseases

1st Edition - January 5, 2022

Editor: Nima Rezaei

Paperback ISBN:

9 7 8 - 0 - 1 2 - 8 2 4 3 9 0 - 9

eBook ISBN:

9 7 8 - 0 - 3 2 3 - 8 5 9 7 5 - 2

Translational Autoimmunity: Treatment of Autoimmune Diseases, Volume Two in the Translational Immunology series, focuses on advances in therapeutic modalities in autoimmune… Read more

Image - Translational Autoimmunity, Volume 2

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Translational Autoimmunity: Treatment of Autoimmune Diseases, Volume Two in the Translational Immunology series, focuses on advances in therapeutic modalities in autoimmune diseases. Efficacy and safety of not only the current biologic therapies, but also novel drug targets are discussed. Therapeutic targeting of B regulatory cells, T regulatory cells, as well as the immunomodulation effects of nanoparticles and organisms are also covered, along with our understanding and future challenges of prognostic significance of treatments in autoimmune diseases.

Cover image
Title page
Table of Contents
Copyright
Dedication
Contributors
Preface
Series editor biography
Acknowledgment
Abbreviations
Chapter 1: Introduction on therapeutic opportunities for autoimmunity
Abstract
1: Introduction
2: From the very first known treatment to the recent developments in therapeutic strategies
3: Conclusion
References
Chapter 2: Innate lymphoid cells as therapeutic targets in autoimmune diseases
Abstract
1: Introduction
2: The biology of innate lymphoid cells
3: Properties and functions of ILCs
4: ILC in autoimmune diseases
5: ILCs as immunoregulators in autoimmune diseases
6: ILC as a potential therapeutic target in autoimmune diseases
7: Future perspectives
8: Conclusion
References
Chapter 3: B regulatory cells in patients with autoimmune diseases: Pathogenic significance and therapeutic potential
Abstract
1: Introduction
2: Identification of Breg cells
3: Functional properties
4: B regulatory cells and autoimmunity: Pathogenic significance
5: Therapeutic potential
6: Conclusion
References
Chapter 4: Regulatory T cells in autoimmunity and potential therapeutic targets
Abstract
1: Introduction
2: Discovery of Treg cells
3: Development and activation of Treg cells
4: FoxP3—The transcriptional master regulator of Treg cells
5: Phenotype of Treg cells
6: Treg/T cell subtypes with regulatory function
7: Protocols for estimation of Treg cells in the peripheral blood
8: Isolation of Treg cells for therapeutic purposes
9: Tissue-resident Treg cells
10: Clinical and translational significance of Treg cells
11: Regulatory T cells (Tregs) as potential therapeutic targets
12: Conclusion
References
Chapter 5: Application of IL-6 antagonists in autoimmune disorders
Abstract
1: Introduction
2: Signaling
3: Roles of IL-6
4: IL-6 in ADs and autoimmune-related disorders
5: Laboratory clues
6: IL-6 blockade
7: Conclusion
References
Chapter 6: The search for monomer-interaction-based alternative TNF-α therapies
Abstract
1: Introduction
2: TNF-α in relation to stages in life
3: Structure of TNF-α
4: TNF-α therapies
5: Conclusion
References
Chapter 7: Generation of thymic cells from pluripotent stem cells for basic research and cell therapy
Abstract
Acknowledgments
1: Introduction
2: Thymus organogenesis
3: Thymus function
4: Common thymic disorders
5: Human pluripotent stem cells to TECs: A new frontier
6: Mimicking development in vitro to generate hPSC-derived anterior foregut endoderm
7: Generating thymic epithelial progenitor cells in vitro
8: hPSC-derived thymic epithelial cells
9: In vitro coculture systems to model thymic function
10: Conclusion
References
Chapter 8: The NLRP3 inflammasome pathway in autoimmune diseases: a chronotherapeutic perspective?
Abstract
Fundings
1: Introduction
2: The NLRP3 inflammasome
3: NLRP3 and autoimmune diseases
4: The clock and autoimmune diseases
5: NLRP3 as a chronotherapeutic target for autoimmune diseases treatment
6: Conclusion
References
Chapter 9: Plasmocyte depletion in autoimmune diseases
Abstract
1: Introduction
2: The plasmocyte
3: New drugs targeting the humoral immunity
4: Drugs in the pipeline
5: Autoimmune diseases that may benefit from plasmocyte targeting
6: Conclusion
References
Chapter 10: Biological aging and autoimmunity
Abstract
1: Introduction
2: Immunosenescence
3: Immune and autoimmune theories of aging
4: Autoimmune diseases, cancer, and their relations with aging
5: Conclusion
References
Chapter 11: Efficacy and safety of immune checkpoint inhibitors and cytokine therapy in autoimmune diseases
Abstract
1: Introduction
2: Immunogenicity of mAbs and its effect on efficacy and safety
3: Inflammatory cytokine inhibition in autoimmune diseases
4: ICIs in autoimmune disease
5: Conclusion
References
Chapter 12: Nutritional implications for the pathophysiology and treatment of autoimmune disorders
Abstract
1: Introduction
2: Body composition and metabolic health
3: Dietary patterns
4: Macronutrients
5: Micronutrients
6: Additional non-nutrient dietary factors
7: Conclusion
References
Chapter 13: Dysbiosis and probiotic applications in autoimmune diseases
Abstract
1: Introduction
2: Dysbiosis in autoimmune diseases
3: Dysbiosis in autoimmune diabetes
4: Dysbiosis in autoimmune thyroid diseases
5: Dysbiosis in rheumatoid arthritis
6: Dysbiosis in systemic lupus erythematosus
7: Dysbiosis in Sjögren’s syndrome
8: Probiotic applications in autoimmune diseases
9: Probiotics in autoimmune diabetes
10: Probiotics in autoimmune thyroid diseases
11: Probiotics in rheumatoid arthritis
12: Probiotics in systemic lupus erythematous
13: Probiotics in Sjögren’s syndrome
14: Conclusion
References
Chapter 14: Precision medicine to manage chronic immune-related conditions
Abstract
Acknowledgments
1: Introduction
2: Immunosenescence
3: Diabetes mellitus
4: Atherosclerotic cardiovascular disease
5: Musculoskeletal conditions and arthritis
6: Mental health conditions
7: Cancer
8: Conclusion
References
Chapter 15: New advanced therapy medicinal products in treatment of autoimmune diseases
Abstract
1: Introduction
2: Autoimmune disorders
3: Conclusion
References
Chapter 16: Targeting autoimmune disorders through metal nanoformulation in overcoming the fences of conventional treatment approaches
Abstract
1: Introduction
2: Nanotechnology and nanomaterials
3: Targeting of metal nanoparticles for autoimmune conditions
4: Safety concern of metallic nanoparticles
5: Conclusion
References
Chapter 17: Immunomodulatory effects of parasites on autoimmunity
Abstract
1: Introduction
2: Mechanism of action in helminth therapy
3: Application and protective roles of helminth therapy
4: Current challenges in helminth therapy
5: Animal models for helminth therapy
6: Immunomodulatory roles of parasites on inflammatory or autoimmune diseases
7: Leishmaniasis and autoimmune disorders
8: Toxoplasmosis and autoimmune disorders
9: Conclusion
References
Chapter 18: Prediction of autoimmune diseases: From bench to bedside
Abstract
1: Introduction
2: Using genetics to estimate the risk of developing AIDs
3: Epigenetics to predict AIDs
4: Using antibodies and serum biomarkers to predict AIDs
5: Perspectives
6: Prevention
7: Conclusion
References
Index